Featured Research

from universities, journals, and other organizations

Patients at high risk of recurrences of heart disease: Breakthrough in prevention

Date:
May 24, 2010
Source:
University of Montreal
Summary:
Researchers have announced promising findings of a major clinical study study on VIA-2291 -- a recently developed medication that can effectively reduce inflammation, which can contribute to the formation and progression of atherosclerosis plaque and infarct.

Researchers have announced promising findings of a major clinical study study on VIA-2291 -- a medication developed by Via Pharmaceuticals, a San Francisco-based biotechnology firm, that can effectively reduce inflammation, which can contribute to the formation and progression of atherosclerosis plaque and infarct.

The results of the study, carried out at the Montreal Heart Institute (MHI) by Dr. Jean-Claude Tardif, are now available in the journal Circulation Cardiovascular Imaging. Dr. Tardif is a cardiologist and director of the MHI Research Centre, as well as a professor in the faculty of medicine and holder of the atherosclerosis research chair at the Université de Montréal.

"Up to now, standard treatments for patients with acute coronary syndrome (unstable angina and infarct) have not specifically reduced inflammation, an important component of atherosclerosis. However, research in recent years has allowed us to determine that the presence of inflammation significantly increases the risk of recurrence among these patients. The clinical study was conducted with about 200 patients, and the findings we're publishing show that VIA-2291 may finally offer the solution we need to target and reduce inflammation. In fact, these newly published data strongly support the evaluation of VIA-2291 in larger outcome trials," said Dr. Tardif.

The Montreal Heart Institute's Research Centre directed the study in several hospitals in Canada and the United States as well as analyzed all of the data, including data collected by CAT scans of coronary arteries.

"The publication of this new study attests once again to the excellence of the entire team at the Montreal Heart Institute's Research Centre. While we're clearly satisfied with the findings obtained with VIA-2291, we're even more thrilled at the prospect of taking a big step toward more effective and personalized prevention of cardiovascular disease," concluded Dr. Tardif.


Story Source:

The above story is based on materials provided by University of Montreal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jean-Claude Tardif, Philippe L. L'Allier, Reda Ibrahim, Jean C. Grégoire, Anna Nozza, Mariève Cossette, Simon Kouz, Marc-André Lavoie, Janie Paquin, Tilmann M. Brotz, Rebecca Taub, and Josephine Pressacco. Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome. Circulation Cardiovascular Imaging, 2010; 3: 298-307 DOI: 10.1161/CIRCIMAGING.110.937169

Cite This Page:

University of Montreal. "Patients at high risk of recurrences of heart disease: Breakthrough in prevention." ScienceDaily. ScienceDaily, 24 May 2010. <www.sciencedaily.com/releases/2010/05/100520141242.htm>.
University of Montreal. (2010, May 24). Patients at high risk of recurrences of heart disease: Breakthrough in prevention. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2010/05/100520141242.htm
University of Montreal. "Patients at high risk of recurrences of heart disease: Breakthrough in prevention." ScienceDaily. www.sciencedaily.com/releases/2010/05/100520141242.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Trees Could Save More Than 850 Lives Each Year

Trees Could Save More Than 850 Lives Each Year

Newsy (July 27, 2014) — A national study conducted by the USDA Forest Service found that trees collectively save more than 850 lives on an annual basis. Video provided by Newsy
Powered by NewsLook.com
Google's Next Frontier: The Human Body

Google's Next Frontier: The Human Body

Newsy (July 27, 2014) — Google is collecting genetic and molecular information to paint a picture of the perfectly healthy human. Video provided by Newsy
Powered by NewsLook.com
What's To Blame For Worst Ebola Outbreak In History?

What's To Blame For Worst Ebola Outbreak In History?

Newsy (July 27, 2014) — A U.S. doctor has tested positive for the deadly Ebola virus, as the worst-ever outbreak continues to grow. Video provided by Newsy
Powered by NewsLook.com
Losing Sleep Leaves You Vulnerable To 'False Memories'

Losing Sleep Leaves You Vulnerable To 'False Memories'

Newsy (July 27, 2014) — A new study shows sleep deprivation can make it harder for people to remember specific details of an event. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins